NCHR supports the EPA’s decision to assess the risk for cancer from inhalation exposure to cobalt and cobalt compounds. Other health organizations recognize that cobalt is a likely human carcinogen based on animal studies, and it is important for the EPA to investigate if the same link extends to humans as well. An analysis of the evidence is needed to understand the upper-dose limit and how to prevent dangerous exposures to cobalt and cobalt compounds. By providing these results, we hope organizations create guidelines and requirements that the industry must follow to protect worker’s health and well-being of the public.
Read More »Tag: cancer
Statement by Dr. Diana Zuckerman on Sintilimab at FDA Advisory Committee on Oncologic Drugs
February 10, 2022: NCHR president Dr. Diana Zuckerman testifies to the FDA Advisory Committee on Oncologic Drugs on Sintilimab.
Read More »Biden’s ‘Cancer Moonshot’ Turns Toward Pollution
E&E News, February 3, 2022: President Biden made an emotional pledge to “end cancer as we know it” by reinvigorating the Cancer Moonshot Initiative he first launched in 2016, just one year after his son Beau succumbed to the disease. But experts, including us, point out that there isn’t enough focus on environmental causes of cancer.
Read More »Less Radical Surgery Is a Healthier Choice for Women with Breast Cancer
Experts agree that lumpectomy patients live longer than mastectomy patients with better quality of life. BCT is superior to more radical surgery. Bilateral mastectomy has no survival benefit.
Read More »Mastectomy v. Lumpectomy: Who Decides?
Diana Zuckerman, PhD, National Center for Health Research Approximately 230,000 women in the U.S. will be diagnosed with breast cancer this year. Over the last two decades, research has regularly provided new evidence that breast cancer patients can live just as long – or even longer – with less radical treatment. In the 1990s, research […]
Read More »